Although early studies of Ib for R/R CLL suggested that TP53 aberrancy may still portend inferior survival [119–121], in contemporaneous 1L studies outcomes for patients with TP53-aberrant CLL following BTKi are similar to those for patients with TP53 wild type disease at least with available follow-up. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.